Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Microgynon 21 is a combined oral contraceptive (COC) pill containing two active ingredients: the synthetic progestin **levonorgestrel** (150 mcg) and the synthetic estrogen **ethinylestradiol** (30 mcg). Developed by Bayer, it is indicated for the prevention of pregnancy. The drug works through a multi-faceted mechanism: it suppresses the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, which inhibits the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, thereby preventing ovulation. Additionally, it increases the viscosity of cervical mucus to impede sperm entry and alters the endometrium to reduce the likelihood of implantation. It is typically administered as one tablet daily for 21 consecutive days, followed by a 7-day hormone-free interval to allow for withdrawal bleeding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levonorgestrel + ethinylestradiol (Bayer).